1.png
N2OFF: Save Foods to Target California’s Hemp Market
May 06, 2024 07:13 ET | N2OFF Inc.
More than half of US hemp flower grown in California recently received Pre-Harvest Regulatory Approval in California allowing Save Foods to treat hemp Neve Yarak, Israel, May 06, 2024 (GLOBE...
Skyward_RGB_Logo.png
Skyward Specialty Announces Secondary Offering of Its Common Stock
May 06, 2024 07:12 ET | Skyward Specialty Insurance Group, Inc.
HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”)...
Omega_logo1.png
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 06, 2024 07:00 ET | Omega Therapeutics
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data...
logo.jpg
Join Mobilicom’s Exclusive Live Investor Webinar and Q&A Session on May 9
May 06, 2024 07:00 ET | Mobilicom Limited
SHOHAM, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, is pleased to invite investors to a...
Axsome Logo.png
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024 07:00 ET | Axsome Therapeutics, Inc.
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q...
simply good logo.jpg
The Simply Good Foods Company to Participate in the Goldman Sachs Global Staples Forum
May 06, 2024 07:00 ET | Simply Good Foods USA, Inc.
DENVER, May 06, 2024 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (NASDAQ:SMPL) (“Simply Good Foods” or the “Company”), a developer, marketer and seller of branded nutritional foods and...
eyepoint logo.png
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
May 06, 2024 07:00 ET | EyePoint Pharmaceuticals, Inc.
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no...
Cara logo transparent background 011123.png
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
May 06, 2024 07:00 ET | Cara Therapeutics, Inc.
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Apellis logo.jpg
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024 07:00 ET | Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Bank of America Securities Healthcare...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024 07:00 ET | Foghorn Therapeutics, Inc.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...